The effect of anti-inflammatory drugs on increased vascular permeability induced by chemical mediators.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects*; D002746:Chlorpromazine / Q000494:pharmacology; D005260:Female; D006168:Guinea Pigs; D006632:Histamine / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007610:Kallikreins / Q000494:pharmacology; D010113:Oxyphenbutazone / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology; D011113:Polymyxins / Q000494:pharmacology; D011343:Procaine / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D014311:Triprolidine / Q000494:pharmacology; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D011113:Polymyxins; D011725:Pyridines; D014311:Triprolidine; D003189:p-Methoxy-N-methylphenethylamine; D011343:Procaine; D006632:Histamine; D007610:Kallikreins; D010653:Phenylbutazone; D010113:Oxyphenbutazone; D001241:Aspirin; D001920:Bradykinin; D002746:Chlorpromazine